Clinical Trials Directory

Trials / Completed

CompletedNCT02259309

Immune Modulation by Misoprostol

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Vanderbilt University · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.

Conditions

Interventions

TypeNameDescription
DRUGMisoprostol - buccalbuccal administration
DRUGMisoprostol - vaginalvaginal administration

Timeline

Start date
2014-11-01
Primary completion
2015-07-01
Completion
2015-11-01
First posted
2014-10-08
Last updated
2016-01-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02259309. Inclusion in this directory is not an endorsement.

Immune Modulation by Misoprostol (NCT02259309) · Clinical Trials Directory